Evidence map›Paper›PMID 42910142›Full record

ArticleBreast care (Basel, Switzerland)2026

Tumor Biology, Genetic Risk, and Systemic Therapy in Familial Breast Cancer: An 8-Year Experience from a German Center for Familial Breast and Ovarian Cancer.

Maria Eleni Hatzipanagiotou, Lisa Witterauf, Mikosch Augele, Aviva Fischer, Ivana Holzhauser, Ines Schönbuchner, Simone Hammer, Miriam Fernandez-Pacheco, Deborah Huber, Bernhard H F Weber and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast care (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maria Eleni HatzipanagiotouDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center (CCC) Würzburg, Erlangen, Regensburg, Augsburg (WERA), National Center for Tumor Diseases (NCT), University Medical Center Regensburg, Regensburg, Germany.
Lisa WitteraufDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center (CCC) Würzburg, Erlangen, Regensburg, Augsburg (WERA), National Center for Tumor Diseases (NCT), University Medical Center Regensburg, Regensburg, Germany.
Mikosch AugeleDepartment of Radiology, University Hospital Regensburg, Regensburg, Germany.
Aviva FischerDepartment of Obstetrics and Gynecology, General Hospital Neumarkt, Akademisches Lehrkrankenhaus der Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Ivana HolzhauserInstitute of Human Genetics, University of Regensburg, Regensburg, Germany.
Ines SchönbuchnerInstitute of Human Genetics, University of Regensburg, Regensburg, Germany.
Simone HammerDepartment of Radiology, University Hospital Regensburg, Regensburg, Germany.
Miriam Fernandez-PachecoDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center (CCC) Würzburg, Erlangen, Regensburg, Augsburg (WERA), National Center for Tumor Diseases (NCT), University Medical Center Regensburg, Regensburg, Germany.
Deborah HuberHospital Dritter Orden, Obstetrics and Gynaecology, Munich, Germany.
Bernhard H F WeberInstitute of Human Genetics, University of Regensburg, Regensburg, Germany.
Davor LesselInstitute of Human Genetics, University of Regensburg, Regensburg, Germany.
Olaf OrtmannDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center (CCC) Würzburg, Erlangen, Regensburg, Augsburg (WERA), National Center for Tumor Diseases (NCT), University Medical Center Regensburg, Regensburg, Germany.
Stephan SeitzDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center (CCC) Würzburg, Erlangen, Regensburg, Augsburg (WERA), National Center for Tumor Diseases (NCT), University Medical Center Regensburg, Regensburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Approximately 30% of breast cancer cases involve a significantly increased familial risk, often associated with pathogenic germline mutations. This study evaluates the spectrum of pathogenic variants identified, systemic therapy patterns, tumor biology, and treatment response among breast cancer patients treated at the Regensburg Center of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) between 2012 and 2020. Methods: A retrospective analysis was performed on 385 breast cancer patients who met the GC-HBOC criteria for elevated familial risk. Patients were categorized based on genetic status (pathogenic Results: In this study, pathogenic variants in established breast and ovarian cancer-predisposing genes were identified in 49%, primarily in Conclusion: The study demonstrates the effective implementation of genetic testing and guideline-based therapy in a real-world, high-risk breast cancer cohort.

Indexed as

BRCA1/2 mutationsHereditary breast cancerNeoadjuvant chemotherapyPathological complete responsePlatinum-based therapyTriple-negative breast cancer

Identifiers

PMID42910142
PMCPMC13685052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.